Development of a new cyclosporine formulation based on poly(caprolactone) microspheres

被引:49
作者
Aberturas, MR [1 ]
Molpeceres, J [1 ]
Guzmán, M [1 ]
García, F [1 ]
机构
[1] Univ Alcala de Henares, Dept Farm & Tecnol Farmaceut, Madrid 28871, Spain
关键词
microspheres; cyclosporine; stability; poly( caprolactone); lyophilization;
D O I
10.1080/02652040110055270
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The present study describes the development of a new cyclosporine formulation based on polycaprolactone (PCL) microspheres (MS) prepared by the solvent evaporation method. Ternary phase diagrams were used to identify the domains where MS were formed. The application of central composite designs established the influence of several technological (stirring speed) and formulation factors (polymer and surfactant amounts, and organic solvent volume) on the size of PCL MS. Cyclosporine-loaded MS of a size around 2.5 mum were prepared and characterized. The stability of the systems, either alone or loaded with cyclosporine, stored at 8degreesC and room temperature (RT) was assessed as well. Freeze-drying was evaluated as an alternative method to achieve long-term stability. The experimental design showed that the stirring speed and the organic phase volume were the only parameters significantly affecting the MS size. Experimental conditions selected to obtain CyA-loaded MS of 2.5 mum resulted in a high entrapment percentage. 98.4 +/- 0.66%), with the drug dissolved or molecularly dispersed within the dense polymeric matrix of MS. After 12 months of storage at 8degreesC and RT, PCL MS remained physically stable, although the crystallinity of the polymer increased by 35% upon storage at both temperatures. Freeze-drying studies revealed that MS could be successfully lyophilized in the absence of cryoprotectants without significant changes of the drug entrapment; however, the presence of at least 5% cryoprotectant was essential to keep the initial particle size. Therefore, a stable MS-based CyA formulation was easily prepared and characterized. This formulation offer the possibility of CyA administration through different routes.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 29 条
[1]  
Bonduelle S, 1996, EUR J PHARM BIOPHARM, V42, P313
[2]   RECENT ADVANCES ON THE USE OF BIODEGRADABLE MICROPARTICLES AND NANOPARTICLES IN CONTROLLED DRUG-DELIVERY [J].
BRANNONPEPPAS, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 116 (01) :1-9
[3]   Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A [J].
Calvo, P ;
Sanchez, A ;
Martinez, J ;
Lopez, MI ;
Calonge, M ;
Pastor, JC ;
Alonso, MJ .
PHARMACEUTICAL RESEARCH, 1996, 13 (02) :311-315
[4]   A ONE-WEEK SUBDERMAL DELIVERY SYSTEM FOR L-METHADONE BASED ON BIODEGRADABLE MICROCAPSULES [J].
CHA, Y ;
PITT, CG .
JOURNAL OF CONTROLLED RELEASE, 1988, 7 (01) :69-78
[5]   Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers [J].
Chacón, M ;
Molpeceres, J ;
Berges, L ;
Guzmán, M ;
Aberturas, MR .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (02) :99-107
[6]   Optimized preparation of poly D,L (lactic-glycolic) microspheres and nanoparticles for oral administration [J].
Chacon, M ;
Berges, L ;
Molpeceres, J ;
Aberturas, MR ;
Guzman, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 141 (1-2) :81-91
[7]   BIODEGRADABLE PSEUDOLATEXES - THE CHEMICAL-STABILITY OF POLY(D,L-LACTIDE) AND POLY (EPSILON-CAPROLACTONE) NANOPARTICLES IN AQUEOUS-MEDIA [J].
COFFIN, MD ;
MCGINITY, JW .
PHARMACEUTICAL RESEARCH, 1992, 9 (02) :200-205
[8]   NANOPARTICLES AND MICROPARTICLES FOR THE DELIVERY OF POLYPEPTIDES AND PROTEINS [J].
COUVREUR, P ;
PUISIEUX, F .
ADVANCED DRUG DELIVERY REVIEWS, 1993, 10 (2-3) :141-162
[9]   Is trehalose special for preserving dry biomaterials? [J].
Crowe, LM ;
Reid, DS ;
Crowe, JH .
BIOPHYSICAL JOURNAL, 1996, 71 (04) :2087-2093
[10]   Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles:: Influence on physical stability and in vitro cell uptake [J].
De Jaeghere, F ;
Allémann, E ;
Leroux, JC ;
Stevels, W ;
Feijen, J ;
Doelker, E ;
Gurny, R .
PHARMACEUTICAL RESEARCH, 1999, 16 (06) :859-866